Chapter 39: Antibiotics That Inhibit Bacterial Protein Synthesis

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today involves a bit of heavy lifting, I think.

I've been reading through chapter 39 of Brenner and Stevens Pharmacology, the sixth edition, and I have to say the title, Antibiotics That Inhibit Bacterial Protein Synthesis,

it doesn't quite capture the drama of what's actually happening here.

No, it really doesn't.

We are essentially reading a manual on microscopic sabotage.

That is a very, very apt way to put it.

I mean, when you look at the sheer variety of ways these drugs jam the gears of bacterial machinery, it really is a form of warfare.

We aren't just, you know, poisoning the bacteria.

We're literally dismantling their assembly lines while they're still trying to run.

And that's the mission for this session, right?

We're not just going to memorize a bunch of drug names like we're cramming for a board exam, though.

I mean, if you are, this will definitely help.

We're going to break down the mechanics.

We want to really understand this massive class of antibiotics that target the ribosome, stopping bacteria from building the very proteins they need to survive.

Which I think brings us to the most obvious problem.

So the first question that struck me when I started studying this stuff,

humans are made of protein.

I mean, we build proteins every second of every day just to stay alive.

Right.

So if we ingest a drug that's designed to stop protein synthesis, why doesn't it just shut down our own bodies?

Why doesn't it kill us along with the infection?

Exactly.

It's the selective toxicity puzzle.

And I was looking at the comparison in the text between bacterial ribosomes and human ribosomes.

And honestly, at first glance, the difference seems, well, it seems dangerously thin.

It all comes down to a numbers game, these Fedberg units.

It does.

But those numbers, they represent a very real physical reality.

To a non -chemist, density or sedimentation rate might sound abstract, but for a drug molecule, it's the difference between a locked door and a wide open one.

See, bacteria are prokaryotes.

They use what we classify as 70S ribosomes.

Okay.

And that 70S structure is made of two parts.

The text breaks it down into a 30S subunit and a 50S subunit.

And before anyone tries to do the math at home, I already checked 30 plus 50 does not equal 70 in standard addition.

No, it absolutely does not.

It's a common stumbling block.

Fedberg units, they measure the sedimentation rate in a centrifuge, not simple mass or weight, so they don't add up linearly.

But the key takeaway isn't the math, it's the shape and the structure.

That 70S ribosome is the target.

And humans, because we're eukaryotes, we use 80S ribosomes, which are made of 40S and 60S subunit.

So structurally, our ribosomes are just a bit larger, a bit denser.

And that's enough.

It's just different enough that these drugs, we're talking tetracyclines,

aminoglycosides, macrolides, they are designed, shaped to bind to the bacterial 70S version, but they just sort of bounce right off our 80S version.

It's a classic lock and key mechanism.

The key we're using simply does not fit the human lock.

But there's a small caveat here, right?

The text makes a point of mentioning mitochondria.

Yes, and this is just fascinating from an evolutionary perspective.

Our mitochondria, the power plants inside our cells,

are thought to have originated from ancient bacteria that our ancestors engulfed billions of years ago.

It's called the endosymbiotic theory.

So they still have some of that ancient machinery.

They do.

They actually possess 70S -like ribosomes.

Which implies that if we push the dose of these antibiotics way too high, we might start accidentally sabotaging our own mitochondria.

Potentially, yes.

And that's likely the source of some of the toxicities we see with these drugs at high concentrations.

But generally, the drug has a much, much harder time getting inside the mitochondrial membrane compared to getting inside a bacterium.

So the selectivity holds up pretty well under normal circumstances.

Okay, so let's talk about where these microscopic weapons came from.

We aren't the first ones to think of poisoning ribosomes.

The text mentions the post -penicillin era, where scientists were just scrambling to find something, anything, that worked on bugs that penicillin couldn't touch.

Penicillin was a miracle drug, but it targets the cell wall.

And bacteria are incredibly clever.

They developed resistance mechanisms very quickly.

So in the mid -20th century, the search shifted from mold on a petri dish to, well, the soil.

Specifically, the streptomyces genus of bacteria.

It feels like half the drugs in this entire chapter came from streptomyces.

It's mentioned over and over.

They're the original chemical warfare experts.

I mean, in the soil, it's a brutal constant fight for resources.

These bacteria evolved over millennia to secrete these complex, beautiful molecules, specifically designed to kill their neighbors by shutting down their protein factories.

We didn't invent these weapons.

We just harvested them.

So aminoglycosides, tetracyclines, macrolides, they all trace their lineage back to this warfare in the dirt.

They do.

And streptomycin was the first really big breakthrough from that search.

Which was a massive deal for tuberculosis.

Huge.

Absolutely world changing.

Before streptomycin, a TB diagnosis was often a slow, inexorable death sentence.

This drug opened the door to actually curing it for the first time in human history.

Okay.

Let's visualize the battlefield.

The text provides a great diagram, figure 39 .1 of the bacterial ribosome.

I want to build this mental image really carefully because I think everything else we discussed today depends on it.

So we have the 30S subunit on the bottom and the 50S subunit on the top.

You can think of it like a hamburger bun or maybe a factory floor with two levels.

The 30S is the bottom floor.

Let's call it the decoding center.

Its whole job is to read the blueprint.

And the blueprint is the messenger RNA, the mRNA.

It just slides through that 30S subunit.

Exactly.

And the top floor, the 50S subunit, that's the assembly center.

That's where the real work gets done.

That's where the peptidyl transferase enzyme lives.

Its job is to be the welder, linking the amino acids together into a long chain.

So the whole process, the book calls it initiation, elongation, termination.

It works like an assembly line.

The mRNA blueprint runs along the bottom.

And then these little trucks, the transfer RNA or tRNA, they bring in the amino acids, the raw materials, and they match them to the code on the blueprint.

Right.

And there are specific loading docks on this assembly line.

The tRNA carrying the next amino acid enters at the A site.

You can think of A for amino acid entry or acceptor.

Okay.

So the truck pulls into the A site.

If it's cargo,

the amino acid matches the code on the blueprint.

It moves over to the P site, the peptidyl site.

That's where the growing protein chain is currently hanging.

The ribosomes welder, that peptidyl transferase, then connects the new amino acid onto the chain.

And then the whole machine moves forward one notch.

Exactly.

That ratcheting forward is called translocation.

And then the now empty tRNA truck leaves through the final bay, the E site, for exit.

And the whole cycle repeats over and over at incredible speed.

It's a high speed, high precision operation.

It is.

Until we introduce these antibiotics.

And we can group them into two main teams based on which floor of the factory they decide to attack.

We have team 30S, which attacks the decoding center on the bottom.

And team 50S, which attacks the welding and assembly center up top.

Let's start with team 30S then.

The two heavy hitters here are the tetracyclines and the amino glycosides.

But looking at their mechanisms, even though they both target the 30S, they work in completely different ways.

Oh, night and day.

It's a fantastic contrast.

Let's look at the tetracyclines first.

Mechanically, you can think of them as the bouncers at a club.

They bind to the 30S subunit right at the A site.

The entry door.

The only entry door.

So a tRNA molecule arrives with the next amino acid.

It's trying to deliver its payload.

But the tetracycline molecule is physically sitting in its parking spot.

It competitively blocks the tRNA from binding.

So the assembly line doesn't break, it just pauses, it stalls.

It freezes, exactly.

No new ingredients can enter the factory.

And this is a really crucial distinction.

This makes tetracyclines bacteria static.

They stop the bacteria from growing and multiplying, but they don't kill it outright.

So if you take the drug away.

If you remove the drug, the blockade lifts, the bouncer goes home.

And protein synthesis can resume.

That's why with bacteriostatic drugs, we are heavily relying on the patient's own immune system to come in and mop up the stunned static bacteria.

Okay, so let's contrast that with the aminoglycosides.

These guys seem much more aggressive.

The text describes them as bactericidal.

They actually kill the bacteria.

Why does binding to the same 30S subunit result in death instead of just a pause?

Because aminoglycosides don't just block the door.

They sabotage the entire translation process.

They bind to the 30S subunit, but they cause it to distort its shape.

It's like warping the reading glasses of the ribosome.

The blueprint, the mRNA, is still there and is still being fed through, but the ribosome reads it all wrong.

So it starts grabbing the wrong parts, putting in the wrong ingredients.

Yes, it starts incorporating incorrect amino acids into the growing protein chain.

It produces absolute junk proteins.

These are misfolded mutant proteins that can't perform their normal functions.

But it's actually worse than that.

How can it be worse than that?

Because these junk proteins often get inserted into the bacterial cell membrane and they create pores and leaks.

The structural integrity of the cell wall starts to fail.

So the bacteria isn't just being starved of useful proteins.

It's actively poisoning itself with broken machinery that then pokes holes in its own skin.

Correct, and that damage is catastrophic and irreversible.

That's why aminoglycosides are bactericidal.

Chaos strategy versus the tetracycline blockade strategy.

Okay, that makes sense.

So moving upstairs to Team 50S, we've got the macrolides, chloramphenicol, and clindamycin.

What's the strategy on this level of the factory?

Most of these drugs focus on either the welding process itself or the movement of the assembly line.

Macrolides, for instance, they bind to the 50S subunit and they block the exit tunnel where the new protein chain is supposed to emerge from.

Like plugging the exhaust pipe on a car.

That's a great analogy.

But more specifically, their primary mechanism is inhibiting translocation.

They physically prevent the ribosome from ratcheting forward from the A site to the B site.

The whole conveyor belt just gets stuck in place.

And what about chloramphenicol?

Where does it hit?

Chloramphenicol targets the welder directly.

It inhibits the peptidyl transferase enzyme.

So the amino acids are there.

The blueprint is being read correctly.

But the chemical bond that links them together, that peptide bond, simply cannot be formed.

It's just amazing how specific these molecular targets are.

It's like each drug class found a unique vulnerability.

Let's dive deeper into the clinical reality of this.

We're on part one, drugs that affect the 30S subunit.

Now we're starting with the chaos agents, the amino glycosides.

The roster in the book includes gentamicin, topamycin, amicusin, and of course streptomycin.

And a newer one, plasomycin, which is important for resistance.

Now the single most important thing to understand about amino glycosides isn't just their mechanism, but their chemistry.

The text really emphasizes that they are highly ionized polycationic molecules.

Which means they carry a strong positive charge in the body.

And in practical terms, reading through the pharmacokinetics section, this one chemical property seems to dictate everything about how we have to use them.

It dictates absolutely everything.

Because they're so highly charged, they love water, they're hydrophilic, and they hate fat.

They're lipophobic.

And what are biological membranes, like the lining of your gut, made up?

Lipids, fats.

Right.

So if you have a systemic infection, let's say sepsis, or bad pneumonia, and you swallow a pill of gentamicin, what happens?

Nothing.

Absolutely nothing.

It will travel through your stomach, through your intestines, and it will come out completely unchanged in the feces.

You get 0 % absorption.

It cannot cross that lipid wall of the gut.

And that explains why the text is so clear that they must be given

IV or IM by needle for any systemic infection.

Are there any exceptions at all?

The only exception is if the infection is inside the gut tube itself.

For example, a surgeon might give oral neomycin to sterilize the bowel before a big abdominal surgery, or to treat an intestinal parasite like an amoeba.

In that case, we are relying on the fact that it stays in the gut and doesn't get absorbed.

But for anything in the blood, lungs, or tissues, you need a needle.

And this charge issue, it creates barriers elsewhere in the body, too.

The text mentions they don't enter cells very well.

They have a low volume of distribution.

And critically, they don't cross the blood -brain barrier.

Which is a huge problem if you're trying to treat meningitis.

The meninges, the lining of the brain, are protected by that very tight barrier.

Ammonic glycosides just can't get through in any meaningful concentration unless the meninges are severely inflamed.

And even then, it's pretty unreliable.

Okay, now, elimination.

This is a major safety flag that the chapter raises.

These drugs are cleared 100 % by the kidneys, and they're cleared unchanged.

They are filtered right out by the glomerulus.

The clinical rule of thumb is this.

The clearance of ammonic glycosides is equal to the patient's creatinine clearance.

This is vital because if a patient has kidney failure, or even just mild renal insufficiency, the drug has nowhere to go.

It can't get out of the body.

It just stays in the blood.

It stays, and it accumulates.

And if it accumulates, well, that's when we get to the really nasty toxicity section.

The big two toxicities for ammoglycosides are infamous in medicine.

Nephrotoxicity and ototoxicity.

Let's break those down.

Nephrotoxicity, that's kidney damage.

How does that happen?

It happens because the drug isn't just filtered by the kidney.

It's actively transported into the cells of the proximal tubule.

It gets trapped there at very high concentrations, and it starts to poison those cells, causing cell death, a condition called acute tubular necrosis.

The text does note this is usually reversible.

If you catch it early and stop the drug, the kidney can heal itself.

Usually, yes.

The kidney is a remarkably resilient organ.

But the ear, the ear is a completely different story.

Ototoxicity, or ear toxicity, is one that keeps pharmacists and infectious disease doctors up at night.

The mechanism here is honestly terrifying.

It says the drug accumulates in the inner ear fluids, the paralymph and endolymph.

And from there, it gets into the hair cells of the cochlea and the vestibule.

It triggers apoptosis programmed cell suicide in those hair cells.

These are the incredibly delicate sensory cells that translate sound vibrations and head movements into nerve impulses.

Once those hair cells die, they are gone forever.

Humans cannot regenerate them.

So the hearing loss is permanent, and it's not just hearing, is it?

It's balance too.

Correct.

The inner ear controls both.

So you can get cochlear toxicity, which presents as tinnitus, or ringing in the ears, and high frequency hearing loss.

Or you can get vestibular toxicity, which causes vertigo, dizziness, and a loss of balance.

The text points out that different drugs in the class have different affinities.

Gentamicin and streptomycin tend to destroy balance first.

Amicusin tends to go for hearing first.

This all brings us to the dosing strategy.

Because the difference between a therapeutic dose and a toxic dose is so incredibly narrow, we have to be extremely precise.

The text discusses two key concepts.

Concentration -dependent killing and the post -antibiotic effect.

Right, and understanding these two things completely changed how we dose these drugs.

We used to give smaller doses, maybe three times a day.

But then we learned that aminoglycosides kill bacteria faster and more completely when the concentration spike is huge.

That's concentration -dependent killing.

You want a really high peak concentration.

And the post -antibiotic effect.

What's that?

That means the bacteria stay stunned and suppressed, even after the drug concentration in the blood has fallen to zero.

The damage to their ribosomes is so severe that it takes them hours to recover, even with no drug around.

So if you put those two ideas together...

You get the modern strategy of once -daily dosing.

We give one massive dose per day to get a huge peak concentration for maximum killing power.

And then we let the drug levels fall to near zero for the rest of the 24 hours before the next dose.

Why do we want it to fall to zero, though?

Wouldn't that give the bacteria a chance to grow back?

The post -antibiotic effect keeps the bacteria suppressed during that time.

But that washout period when we measure the trough level is absolutely essential for safety.

It gives the cells in the ear and the kidney a break, a chance to clear the drug out of their cyoplasm before the next big wave hits them.

If the trough level stays high, the drug accumulates in the tissue day after day, and that's when you get irreversible deafness and kidney failure.

So it's all about that balance.

A high peak for efficacy, a very low trough for safety.

It's a tightrope walk.

So what exactly are we using these risky drugs for?

What bugs are worth taking this kind of risk?

They are the aerobic gram -negative specialists.

We are talking about the really nasty, often hospital -acquired pathogens.

Things like pseudomonas, aeruginosa, klebsiella, E.

coli.

So serious infections.

Life -threatening ones.

Sepsis, complicated hospital -acquired pneumonia, complicated urinary tract infections.

Streptomycin specifically has a niche history.

It's still a cornerstone for treating tuberculosis, but also for rare but terrifying things like ursineopestis, the plague, and tularemia.

The text also highlights this concept of synergy.

Specifically, using gentamicin alongside a cell wall active drug like penicillin or vancomycin.

Yes, this is the standard of care for serious infections like endocarditis, which is an infection of the heart valves.

The logic is beautiful.

The penicillin, or vancomycin, punches holes in the bacterial cell wall, which then allows the gentamicin to flood into the cell and smash the ribosome.

They work far, far better together than either one does alone.

Before we leave the aminoglycosides, let's just quickly touch on resistance.

How do the bacteria fight back against these chaos agents?

They are incredibly crafty.

The most common mechanism by far is enzymatic modification.

The bacteria evolved to produce enzymes, we call them transferases, that attach little chemical groups like an acetyl group or a phosphate group onto the aminoglycoside molecule itself.

So they basically graffiti the drug molecule.

That's a perfect way to put it.

And that modification changes the drug's shape just enough that it can no longer bind to the ribosome.

It just bounces off.

This is why we have a drug like plasmicid.

It was specifically engineered to be resistant to those modifying enzymes.

But even that's not foolproof.

Bacteria can also change the ribosome itself through methylation, or they can just install powerful pumps to kick the drug out.

It's a constant battle.

Okay, let's switch gears to the other 30S squad, the tetracyclines.

This group includes tetracycline itself.

Doxycycline, minocycline, and the newer one, tigecycline.

A very, very different class of drugs.

While aminoglycosides are these dangerous high -power drugs used mostly in hospitals, tetracyclines are kind of the Swiss army knives of outpatient medicine.

But they have a very specific chemical quirk that every single listener needs to know about.

Chelation.

The milk rule.

I feel like this is the one thing everyone remembers from their high school health class about antibiotics.

Don't take them with dairy, but chemically, what is actually happening.

Tetracyclines have a strong negative charge affinity for divalent and trivalent cations.

That's just a fancy way of saying they love to bind to metal ions that have a plus two or plus three charge.

We're talking calcium, magnesium, aluminum, and iron.

So if I drink a big glass of milk, which is obviously full of calcium, right after taking my doxycycline pill.

The drug molecules will physically bind to the calcium ions right there in your stomach.

They form a non -absorbable insoluble complex.

It's basically like a little clump of sand.

It cannot pass through the gut lining.

So the drug never even enters your bloodstream.

It just passes right through your GI tract and out the other end.

And this applies to more than just milk.

What about antacids?

Full of magnesium and aluminum.

Same problem.

Iron supplement.

Full of iron.

Same problem.

Even a daily multivitamin usually has enough of all of the above to significantly reduce absorption.

You have to tell patients to separate the dose of the tetracycline from any of these things by at least two hours.

Okay, so assuming we get the dosing right and avoid the dairy, the absorption is generally pretty good, especially for doxycycline and minocycline.

But the elimination offers a really important surprise here.

Most are renal, but doxycycline is the rebel.

Doxycycline is completely unique in this class, because it is eliminated primarily via the bile into the feces.

It almost entirely bypasses the kidneys.

Which makes it the MVP for patients with renal failure.

Precisely.

If you have a patient who is on dialysis and needs an antibiotic from this family, doxycycline is the go -to choice.

It's safe.

You don't even need to adjust the dose, which is remarkable.

Let's look at the spectrum of activity.

You call them Swiss Army knives, and the list of bugs and conditions in the text is eclectic.

I sometimes call them the weird pathogen drugs.

Yes, they work on some standard stuff, but they are the absolute drug of choice for the oddballs of microbiology.

Rickettsia, for example.

That's Rocky Mountain spotted fever.

From tick bites, exactly.

Also, spirachetes, so that's Lyme disease, another tick -borne illness, and relapsing fever.

Then you have the intracellular bugs like chlamydia and mycoplasma, the common causes of walking pneumonia,

and some sexually transmitted infections.

And then there's the more cosmetic use acne.

Right.

Low -dose tetracyclines, especially minocycline and doxycycline, have been used for decades to treat acne vulgaris.

They suppress the growth of propionobacterium acnes in the skin pores, but they also seem to have a direct anti -inflammatory effect that helps reduce the redness and swelling.

Okay.

And then there is tigcycline.

The text calls it a glycylglycine derivative, which sounds complicated, but clinically it seems like the in case of emergency break glass option.

Tigcycline is a real heady hitter.

It's a derivative designed to overcome common tetracycline resistance mechanisms.

It binds to the 30S ribosome with something like five times the affinity of regular tetracyclines.

So it's very effective against tough bugs like MRSA, methicillin -resistant staph aureus, and VRE.

But there's a major catch, a black box warning from the FDA.

A very significant one.

Several large clinical trials showed a small but consistent increased risk of death in patients who were treated with tigacycline compared to other antibiotics.

We aren't entirely sure why.

One theory is that the drug distributes so widely and effectively into the body's tissues that the levels remaining in the blood stay too low to adequately clear bacteremia.

You know, bacteria is circulating in the blood.

But whatever the reason, the rule is clear.

Use tigacycline only when you have no other good options.

Let's talk about the adverse effects for the whole tetracycline class.

We mentioned the calcium binding with milk, but that powerful affinity for calcium applies to the patient's own body too.

It absolutely does.

Tetracyclines will deposit in any tissue that is actively calcifying.

In a fully grown adult, that's not a huge deal.

But in a fetus or a young child, bones and teeth are actively mineralizing at a rapid rate.

So if a pregnant woman takes a tetracycline?

The drug crosses the placenta, it binds to the calcium in the fetal skeleton, and it can actually inhibit bone growth and cause deformities.

And in children?

The text is very, very specific about this.

Tetracyclines are contraindicated in children under eight years of age.

The drug gets incorporated into the enamel of the permanent teeth while they are still forming under the gums.

When those teeth finally erupt, sometimes years later, they are permanently stained.

A dingy yellow, gray, or brown color.

And it can cause enamel hypoplasia, which means the enamel is thin, weak, and prone to cavities.

So a hard and fast rule.

No tetracyclines for kids under eight or for pregnant women.

There's also the sun issue.

Photosensitivity.

This is a big one.

These drugs accumulate in the skin, and they can absorb UV radiation from sunlight.

Patients can get really severe blistering sunburns with just a few minutes of sun exposure.

Doxycycline is a common offender here.

If you're prescribing this for Lyme disease in the middle of summer, you have to have a serious talk with the patient about wearing hats, long sleeves, and sunscreen.

And one final kind of a horror story from the text.

The danger of expired meds.

Yes, and this is unique to tetracyclines.

Most drugs, when they expire, they just lose potency.

They don't become dangerous.

But tetracyclines degrade over time into toxic byproducts, specifically something called epi - and hydrotetracycline.

If you take these expired pills, it causes a rare but serious condition called Fanconi -like syndrome, a total dysfunction of the kidneys proximal tubules.

So throwing out that old bottle of Doxy from a few years ago isn't just a suggestion, it's a critical safety requirement.

Absolutely.

Never, ever take expired tetracyclines.

Okay, and that covers the ground floor, the 30S subunit.

Let's take the elevator up to the 50S subunit.

This is part two of the chapter.

We're starting with the macrolides, erythromycin, azithromycin, and colithromycin.

Erythromycin is the original, the parent compound, discovered back in 1952.

But frankly, it's a difficult drug to take.

It has a very short half -life, which means you have to take it four times a day, and it causes significant GI distress.

Which led to the development of its children,

azithromycin and clarithromycin.

I mean, azithromycin, the Z -PAC, is probably one of the most prescribed drugs in America.

Why is it so much better from a pharmacokinetic standpoint?

It has this incredible ability to penetrate deep into tissues and then just stay there.

It gets taken up by fibroblasts and immune cells like macrophages, which then act like little taxis, carrying the drug directly to the site of an infection.

And because it's released so slowly from these tissues back into the bloodstream, it has a massive half -life.

That's why you can take a course for just three to five days, but the drug keeps working in your body for up to 10 days.

That explains the convenience factor for sure.

What is their main target spectrum?

We often call them the respiratory trio.

They're the go -to choice for many common upper and lower respiratory infections.

We're talking group A streps, so strep throat, pneumococci, and especially the atypicals bugs like legionella, chlamydian pneumonia, and mycoplasma.

If someone has that nagging cough or a classic case of walking pneumonia, a macrolide is very often the right answer.

Let's go back to the stomach issues for a second.

You mentioned erythromycin is hard to take.

The text explains this isn't just simple irritation, it's a very specific receptor issue.

It is.

It's a fascinating bit of pharmacology.

Erythromycin happens to structurally resemble a gut hormone called motilin, and motilin's only job is to stimulate peristalsis, the contractions that move food through your gut.

So erythromycin binds to and activates motilin receptors, and it triggers these violent premature gut contractions.

So the cramping, the nausea, the diarrhea, it's a direct pharmacological effect, not really a side effect.

Exactly.

The drug is directly mimicking the body's own move things along signal, but at the wrong time and with too much force.

Erythromycin and clarithromycin were chemically modified to have much less of this effect, which is another big reason why they've largely replaced the parent drug.

But there is a pretty serious safety shadow hanging over this class too, and that's CYP3A4 inhibition.

This is an absolutely high yield point for avoiding medical errors.

Erythromycin and clarithromycin are potent inhibitors of cytochrome P4503A4, which is a liver enzyme responsible for metabolizing a huge chunk of all medications on the market.

So if a patient is taking, let's say, a statin drug for high cholesterol.

And you give them clarithromycin, the metabolism of that statin drug grinds to a halt.

The stat levels in the blood can skyrocket to toxic levels.

This can lead to a devastating condition called rhabdomyolysis, that severe muscle breakdown that dumps toxic proteins into the bloodstream and causes acute kidney failure.

Is azithromycin guilty of this drug interaction too?

And this is a key distinction happily no.

The text highlights that azithromycin does not significantly inactivate CYP3A4.

It is chemically distinct enough to avoid that dangerous interaction.

So if your patient is on a complex cocktail of other medications, azithromycin is by far the safer choice from an interaction standpoint.

Next on the 50S roster is clindamycin.

Now, mechanism -wise, the book says it's pretty much the same as the macrolides.

It blocks translocation.

But its clinical use is totally different.

That's right.

Clindamycin has carved out a very specific niche.

It's our anaerobe hunter.

It has excellent activity against bacteria that thrive in oxygen -free environments, like Bactroids fragilis in the gut, which causes abscesses, or Clostridium perfringens, the cause of gas gangrene.

And it also works on some gram positives too, right?

Yes.

It's a very common alternative for skin and soft tissue infections caused by MRSA and strep, especially for patients who have a severe penicillin allergy.

But there is a hidden trap here.

The text presents a case study in box 39 .1 that really brings this home.

Let me set the scene.

You're a sports medicine doctor.

You have a basketball player who took a sharp elbow to the stomach.

A few days later, he's got a fever and a large painful abscess.

You drain it, you send a culture to the lab, and the report comes back.

It's MRSA.

Okay.

A standard situation.

You look at the lab report, the sensitivity panel.

It says the bacteria are resistant to erythromycin, but next to clindamycin, it says susceptible.

So you prescribe clindamycin, but the treatment fails.

The infection just gets worse.

Why?

What went wrong?

What went wrong is that you missed a phenomenon called inducible resistance.

The bacteria carried a specific gene, the erm gene, that codes for an enzyme that methylates the ribosome.

But in the lab, that gene was dormant.

It was switched off.

So the initial test made it look like clindamycin would work.

On the initial test, yes.

But the presence of a macrolide like erythromycin can act as a signal that switches that dormant erm gene on.

Once that gene is activated, the ribosome's shape changes, and clindamycin can no longer bind.

It becomes instantly resistant.

This is where the D -zone test comes in.

Can you describe what a lab technician actually sees on the plate?

Sure.

Imagine a petri dish, an agar plate, with the patient's bacteria growing on it like a lawn.

The tech places a small paper disc with erythromycin on it, and another disc with clindamycin about 15 millimeters apart.

Now, the bacteria grow right up to the erythromycin disc because we already know they're resistant to it.

Around the clindamycin disc, there should be a nice, round, clear circle, a kill zone where the bacteria can't grow.

But if that inducible erm gene is present, something interesting happens.

The erythromycin diffuses out of its disc through the agar, and it wakes up the resistance in the bacteria that are sitting in the area between the two discs.

So those bacteria start to grow into the clindamycin kill zone, but only on the side that's facing the erythromycin disc.

So it flattens that side of the circle.

Exactly.

It turns the round halo of killing into a perfect D shape.

And if you see that D, that's a positive D -zone test, it's a warning sign from the lab.

Do not use clindamycin.

The resistance is there.

It's just waiting to be triggered.

That is brilliant and also kind of terrifying.

Now, clindamycin has a notorious reputation for one specific very serious adverse effect.

Ah, yes.

C.

diff.

Clostridium difficile pseudomembranous colitis.

Now, to be fair, almost all antibiotics can cause this, but clindamycin is historically the worst offender.

It is so effective at wiping out the normal healthy gut flora that C.

diff, which is naturally resistant to clindamycin, can overgrow and take over the whole colon.

It then releases toxins that destroy the colon lining, creating these plaques or pseudomembranes.

This results in massive watery diarrhea that can be debilitating or even fatal.

So a drug to be used with a great deal of respect and caution.

Let's move to the old guard, chloramphenicol.

This is a drug that we have a lot of historical respect for, but one we very rarely use today.

It's a small, wonderfully lipophilic molecule that crosses the blood -brain barrier beautifully.

Decades ago, it was a frontline treatment for bacterial meningitis.

But it's effectively vanished from routine practice in most of the developed world.

Why?

Because of the absolute tragedy of gray baby syndrome.

The name alone is just chilling.

It is.

Back in the 1950s, doctors would give this drug to premature infants to prevent infections.

But what they didn't know was that neonates have very immature livers.

They lack a specific enzyme called glucuronal transferase, which is needed to metabolize and excrete chloramphenicol from the body.

So the drug goes into the baby, but it never leaves.

It just accumulates to staggeringly toxic levels.

And it turns out it interferes with mitochondrial ribosomes.

Remember those 70S lookalikes we talked about in the baby's heart and muscles?

The babies would stop feeding.

They'd become limpid lethargic, have severe respiratory depression, and then turn this awful ashen gray color due to cardiovascular collapse.

Many of them died.

And what about in adults?

Is it safer?

It's safer, but still risky.

It causes bone marrow toxicity.

There's a predictable dose -dependent anemia, which is reversible when you stop the drug.

But there's also a rare, unpredictable, and idiosyncratic aplastic anemia.

It happens in maybe one in 20 ,000 or 40 ,000 people.

It's not related to the dose or how long you take it.

It just happens.

It's a complete shutdown of the bone marrow.

No red cells, no white cells, no platelets.

It's frequently fatal.

And because of that unpredictable risk, chlorine phenicol is now a drug of last resort.

We've got a few more drugs to cover in part three, other protein synthesis inhibitors.

Let's talk about Linazolid.

This one is really important because it's a modern super bug killer.

Linazolid is unique because it hits the ribosome at a completely different time point in the process.

All the other drugs we've discussed so far, they block the process during elongation.

Linazolid stops the process before it even starts.

It prevents the formation of the initiation complex.

It physically stops the 50S subunit from docking onto the 30S subunit to form the functional 70S ribosome.

And because it works so differently, there's no cross resistance, right?

Correct.

If a bacteria has learned how to beat tetracyclines and macrolides and clenomycin, it still has no idea how to handle Linazolid's attack.

And that makes it an invaluable tool for treating infections caused by VRE, vancomycin -resistant enterococcus, and MRSA.

But looking at the safety profile, there's a weird interaction here, too.

Serotonin syndrome.

That seems out of place for an antibiotic.

It does, but it's a real risk.

Chemically, Linazolid is a weak reversible inhibitor of an enzyme called monoamine oxidase, or MAO.

And MAO's job in the brain is to break down neurotransmitters like serotonin.

So if a patient is on an antidepressant, an SSRI like Prozac or Zoloft, that increases serotonin, and you give them Linazolid.

Like block the breakdown pathway.

They can end up with way too much serotonin in their brain synapses.

This can cause agitation, tremors, muscle rigidity, high fever, and confusion.

It's a medical emergency.

It's rare, but you absolutely have to check the patient's medication list before starting Linazolid.

Finally, let's talk about mupirosin.

This one is interesting.

It comes from a bacteria called Pseudomonas fluorescens.

This is a really clever imposter drug.

It is designed to structurally resemble the amino acid isoleucine.

It binds to the enzyme that is supposed to load isoleucine onto its specific tRNA.

So the tRNA truck that is supposed to be carrying isoleucine leaves the depot empty.

Exactly.

And when that empty truck gets to the ribosome assembly line, protein synthesis grinds to a halt because a required ingredient is missing.

And this is only used topically, right?

Specifically for the nose.

Yes, topical only.

Staph aureus, including MRSA, loves to live and colonize in the anterior nerves, the nostrils.

Before major surgeries, especially orthopedic or cardiac surgery, we often have patients apply mupirosin ointment inside their nose for several days to kill off that colonization and prevent the patient from infecting their own surgical wound.

We've covered a massive amount of ground.

To try and synthesize some of this, let's look at the battle plan for MRSA that's summarized in table 39 .4.

If I have a patient with a MRSA infection, what are my protein synthesis inhibitor options from this chapter?

It really depends on the severity.

If it's a more mild skin infection and the patient can swallow pills, you might choose an oral option, like clindamycin, but you have to check for that D -zone of resistance.

Or you could use doxycycline.

Or the big gun, linazolid.

And if it's a severe, life -threatening infection requiring IV therapy?

Then you're going to the parenteral big guns.

Of course, the gold standard is often vancomycin, which isn't in this chapter because it's a cell wall inhibitor.

But from today's discussion, your IV options would be tykecycline, remembering that black box warning or linazolid.

And what about the overall resistance landscape?

Figure 39 .2 in the chapter summarizes how the bacteria are constantly fighting back.

It really is a constant arms race.

And the bacteria have four main moves they can pull.

One, modify the drug.

They build enzymes to chop it up or add chemical groups to it so it can't bind.

That's the main strategy against immunoglycosides.

Okay, what's move two?

Two, modify the target.

They methylate the ribosome itself so the drug can't stick.

That's the arm gene we talked about for macrolides and clindamycin.

Three, kick it out.

They build powerful efflux pumps to spit the drug out as fast as it enters.

Very common for tetracyclines.

And the last one.

And four,

lock the door.

They mutate the porin channels in their outer wall so the drug can't even get inside in the first place.

This is a common strategy for gram -negative bacteria.

It really puts everything into perspective.

We have this incredible, clever toolbox bouncers, chaos agents, welder blockers.

But the bacteria are evolving constantly, finding new ways to counter our every move.

We mentioned lefamulin briefly at the beginning as a new drug.

The first new mechanism in this class in 20 years.

That's a long, long time.

It is a frighteningly long time.

In the two decades while we weren't finding new drugs, the bacteria were very, very busy finding new ways to build resistance.

It definitely makes you wonder, in this microscopic arms race that's happening inside our bodies, are we actually ahead or are we just barely keeping up?

That is a sobering thought to end on.

Well, we hope this deep dive helps you visualize that factory floor and its vulnerabilities the next time you write a prescription or study for an exam or even just take a pill yourself.

And seriously, everyone listening, go check the expiration dates on your old tetracyclines.

Absolutely.

From the Last Minute Lecture Team, thanks for listening.

Stay curious.